Lithium citrate
| Names | |
|---|---|
| Other names
Trilithium citrate
trilithium 2-hydroxypropane-1,2,3-tricarboxylate | |
| Identifiers | |
3D model (JSmol)
|
|
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| DrugBank | |
| ECHA InfoCard | 100.011.860 |
| EC Number |
|
PubChem CID
|
|
| RTECS number |
|
| UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
| Properties | |
| Li3C6H5O7 | |
| Molar mass | 209.923 g mol−1 |
| Appearance | Odorless white powder |
| Melting point | decomposes at 105 °C (221 °F; 378 K) |
| Hazards | |
| GHS labelling: | |
| Warning | |
| H302, H319 | |
| P305+P351+P338 | |
| Flash point | N/A |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references
| |
Lithium citrate (Li3C6H5O7) is a lithium salt of citric acid that is used as a mood stabilizer in psychiatric treatment of manic states and bipolar disorder. There is extensive pharmacology of lithium, the active component of this salt.
Lithium citrate is used to treat mania, hypomania, depression and bipolar disorder. It can be administered orally in the form of a syrup. Liquid lithium, in the form of lithium citrate, is available as an 8 mEq/5 mL solution in the United States.